Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
(NASDAQ:ONCY),(NASDAQ:IMNM),(NASDAQ:PRLD),(NASDAQ:CNTX),(NasdaqGM:RLAY), VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) — Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthroughs[1]. This momentum is already materializing, with five major oncology approvals secured in November across […]